Amgen has announced a dividend of $2.38 per share for the third quarter of 2025. This decision was made by the company’s Board of Directors and marks a significant return for investors. The dividend is scheduled for payment on September 12, 2025, to shareholders who are on record as of the close of business on August 22, 2025.
Based in Thousand Oaks, California, Amgen has been a pioneer in the biotechnology sector for over 40 years. The company has developed a robust portfolio of innovative medicines aimed at treating a variety of serious illnesses, including cancer, heart disease, and rare diseases.
In its continuing effort to advance medical science, Amgen utilizes cutting-edge technology and human genetic data to develop treatments. In 2024, the company was recognized by Fast Company as one of the “World’s Most Innovative Companies.” Additionally, it earned accolades from Forbes, which named it one of “America’s Best Large Employers.” These recognitions highlight Amgen’s commitment to both employee satisfaction and innovation.
Amgen is also a prominent member of major stock indices, including the Dow Jones Industrial Average and the Nasdaq-100 Index. These listings reflect the company’s stature and market capitalization as one of the largest non-financial companies traded on the Nasdaq Stock Market.
The announcement of the dividend comes amidst a backdrop of ongoing strategic collaborations and acquisitions aimed at enhancing Amgen’s product pipeline. The company has entered into collaborations with firms such as BeOne Medicines Ltd. and Kyowa Kirin Co., Ltd., and has also acquired ChemoCentryx, Inc. and Horizon Therapeutics plc. These efforts are intended to bolster Amgen’s ability to deliver innovative therapies and expand its market reach.
As with any forward-looking statements, there are inherent risks and uncertainties associated with Amgen’s operations. The company acknowledges challenges such as competition from other pharmaceutical products, regulatory hurdles, and potential supply chain disruptions. Amgen’s ability to maintain its dividend and continue fulfilling its financial commitments may be influenced by these factors.
For more detailed information about Amgen’s operations, products, and financial performance, visit the company’s official website at Amgen.com or follow them on social media platforms including X, LinkedIn, Instagram, YouTube, and Threads.
In conclusion, Amgen’s declaration of a $2.38 dividend signals its ongoing commitment to reward shareholders while pursuing its mission to improve patient outcomes through innovative medical solutions.
